{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:31:01Z","timestamp":1779917461844,"version":"3.53.1"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1011383","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000}}],"reference-count":116,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12174007"],"award-info":[{"award-number":["12174007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12090054"],"award-info":[{"award-number":["12090054"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key R&D Program in China","award":["2018YFA0900200"],"award-info":[{"award-number":["2018YFA0900200"]}]},{"name":"National Key R&D Program in China","award":["2020YFA0906900"],"award-info":[{"award-number":["2020YFA0906900"]}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>Once challenged by the SARS-CoV-2 virus, the human host immune system triggers a dynamic process against infection. We constructed a mathematical model to describe host innate and adaptive immune response to viral challenge. Based on the dynamic properties of viral load and immune response, we classified the resulting dynamics into four modes, reflecting increasing severity of COVID-19 disease. We found the numerical product of immune system\u2019s ability to clear the virus and to kill the infected cells, namely immune efficacy, to be predictive of disease severity. We also investigated vaccine-induced protection against SARS-CoV-2 infection. Results suggested that immune efficacy based on memory T cells and neutralizing antibody titers could be used to predict population vaccine protection rates. Finally, we analyzed infection dynamics of SARS-CoV-2 variants within the construct of our mathematical model. Overall, our results provide a systematic framework for understanding the dynamics of host response upon challenge by SARS-CoV-2 infection, and this framework can be used to predict vaccine protection and perform clinical diagnosis.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1011383","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T17:36:26Z","timestamp":1693589786000},"page":"e1011383","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Dynamical modelling of viral infection and cooperative immune protection in COVID-19 patients"],"prefix":"10.1371","volume":"19","author":[{"given":"Zhengqing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3407-0819","authenticated-orcid":true,"given":"Jingpeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1483-1820","authenticated-orcid":true,"given":"Fangting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"issue":"6504","key":"pcbi.1011383.ref001","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID\u201319 patients","volume":"369","author":"J Hadjadj","year":"2020","journal-title":"Science"},{"issue":"6490","key":"pcbi.1011383.ref002","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID\u201319","volume":"368","author":"JB Moore","year":"2020","journal-title":"Science"},{"issue":"19","key":"pcbi.1011383.ref003","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid\u201319\u2014Final Report","volume":"383","author":"JH Beigel","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"pcbi.1011383.ref004","doi-asserted-by":"crossref","first-page":"e3001128","DOI":"10.1371\/journal.pbio.3001128","article-title":"A quantitative model used to compare within\u2013host SARS\u2013CoV\u20132, MERS\u2013CoV, and SARS\u2013CoV dynamics provides insights into the pathogenesis and treatment of SARS\u2013CoV\u20132","volume":"19","author":"KS Kim","year":"2021","journal-title":"PLoS Biol"},{"issue":"5","key":"pcbi.1011383.ref005","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life\u2013threatening COVID\u201319: A Randomized Clinical Trial","volume":"324","author":"L Li","year":"2020","journal-title":"JAMA"},{"issue":"17","key":"pcbi.1011383.ref006","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID\u201319 patients","volume":"117","author":"K Duan","year":"2020","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"2","key":"pcbi.1011383.ref007","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","article-title":"Safety and efficacy of inhaled nebulised interferon beta\u20131a (SNG001) for treatment of SARS\u2013CoV\u20132 infection: a randomised, double\u2013blind, placebo\u2013controlled, phase 2 trial","volume":"9","author":"PD Monk","year":"2021","journal-title":"The Lancet Respiratory Medicine"},{"key":"pcbi.1011383.ref008","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022926","article-title":"Dexamethasone in Hospitalized Patients with Covid\u201319\u2014Preliminary Report.","author":"The\u2013RECOVERY\u2013Collaborative\u2013Group","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"32","key":"pcbi.1011383.ref009","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID\u201319 vaccines","volume":"39","author":"KA Earle","year":"2021","journal-title":"Vaccine"},{"issue":"7","key":"pcbi.1011383.ref010","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS\u2013CoV\u20132 infection","volume":"27","author":"DS Khoury","year":"2021","journal-title":"Nature Medicine"},{"issue":"2","key":"pcbi.1011383.ref011","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s43588-022-00198-0","article-title":"Modeling how antibody responses may determine the efficacy of COVID\u201319 vaccines","volume":"2","author":"P Padmanabhan","year":"2022","journal-title":"Nature Computational Science"},{"key":"pcbi.1011383.ref012","first-page":"84","article-title":"Accelerating model\u2013informed decisions for COVID\u201319 vaccine candidates using a model\u2013based meta\u2013analysis approach","author":"B Kandala","year":"2022","journal-title":"EBioMedicine"},{"issue":"2","key":"pcbi.1011383.ref013","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41591-021-01230-y","article-title":"Looking beyond COVID\u201319 vaccine phase 3 trials","volume":"27","author":"JH Kim","year":"2021","journal-title":"Nature Medicine"},{"key":"pcbi.1011383.ref014","first-page":"372","article-title":"Estimated transmissibility and impact of SARS\u2013CoV\u20132 lineage B.1.1.7 in England","author":"NG Davies","year":"2021","journal-title":"Science"},{"issue":"10313","key":"pcbi.1011383.ref015","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(21)02276-5","article-title":"Non\u2013pharmaceutical interventions, vaccination, and the SARS\u2013CoV\u20132 delta variant in England: a mathematical modelling study","volume":"398","author":"R Sonabend","year":"2021","journal-title":"The Lancet"},{"key":"pcbi.1011383.ref016","article-title":"Rapid epidemic expansion of the SARS\u2013CoV\u20132 Omicron variant in southern Africa","volume":"2021","author":"R Viana","year":"2021","journal-title":"medRxiv"},{"issue":"7","key":"pcbi.1011383.ref017","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid\u201319 Vaccines against the B.1.617.2 (Delta) Variant","volume":"385","author":"J Lopez Bernal","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"7871","key":"pcbi.1011383.ref018","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS\u2013CoV\u20132 variant Delta to antibody neutralization","volume":"596","author":"D Planas","year":"2021","journal-title":"Nature"},{"key":"pcbi.1011383.ref019","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS\u2013CoV\u20132","author":"SI Lihong Liu","year":"2021","journal-title":"Nature"},{"key":"pcbi.1011383.ref020","article-title":"Fanchong Jian, Tianhe Xiao, Weiliang Song, Ayijiang Yisimayi, Weijin Huang, Qianqian Li, Peng Wang, Ran An, Jing Wang, Yao Wang, Xiao Niu, Sijie Yang, Hui Liang, Haiyan Sun, Tao Li, Yuanling Yu, Qianqian Cui, Shuo Liu, Xiaodong Yang, Shuo Du, Zhiying Zhang, Xiaohua Hao, Fei Shao, Ronghua Jin, Xiangxi Wang, Junyu Xiao, Youchun Wang & Xiaoliang Sunney Xie Omicron escapes the majority of existing SARS\u2013CoV\u20132 neutralizing antibodies","author":"JW Yunlong Cao","year":"2021","journal-title":"Nature"},{"issue":"7","key":"pcbi.1011383.ref021","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41591-020-0944-y","article-title":"A single\u2013cell atlas of the peripheral immune response in patients with severe COVID\u201319","volume":"26","author":"AJ Wilk","year":"2020","journal-title":"Nat Med"},{"key":"pcbi.1011383.ref022","unstructured":"COVID A. Assessment of Evidence for COVID\u201319\u2013Related Treatments [Available from: https:\/\/www.ashp.org\/\u2013\/media\/assets\/pharmacy\u2013practice\/resource\u2013centers\/Coronavirus\/docs\/ASHP\u2013COVID\u201319\u2013Evidence\u2013Table.ashx."},{"issue":"11","key":"pcbi.1011383.ref023","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41577-020-00455-1","article-title":"Keeping track of the SARS\u2013CoV\u20132 vaccine pipeline","volume":"20","author":"EPK Parker","year":"2020","journal-title":"Nature Reviews Immunology"},{"issue":"13","key":"pcbi.1011383.ref024","doi-asserted-by":"crossref","first-page":"6971","DOI":"10.1073\/pnas.94.13.6971","article-title":"Virus dynamics and\u2009drug\u2009therapy","volume":"94","author":"S Bonhoeffer","year":"1997","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"5386","key":"pcbi.1011383.ref025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon\u2013\u03b1 Therapy","volume":"282","author":"AU Neumann","year":"1998","journal-title":"Science"},{"issue":"9","key":"pcbi.1011383.ref026","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1073\/pnas.93.9.4398","article-title":"Viral dynamics in hepatitis B virus infection","volume":"93","author":"MA Nowak","year":"1996","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"1","key":"pcbi.1011383.ref027","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nri700","article-title":"Modelling viral and immune system dynamics","volume":"2","author":"AS Perelson","year":"2002","journal-title":"Nature Reviews Immunology"},{"issue":"5255","key":"pcbi.1011383.ref028","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","article-title":"HIV\u20131 dynamics in vivo: virion clearance rate, infected cell life\u2013span, and viral generation time","volume":"271","author":"AS Perelson","year":"1996","journal-title":"Science"},{"issue":"1","key":"pcbi.1011383.ref029","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jtbi.2006.12.015","article-title":"A dynamical model of human immune response to influenza A virus infection","volume":"246","author":"B Hancioglu","year":"2007","journal-title":"Journal of Theoretical Biology"},{"key":"pcbi.1011383.ref030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jtbi.2015.03.017","article-title":"The inflammatory response to influenza A virus (H1N1): An experimental and mathematical study","volume":"374","author":"I Price","year":"2015","journal-title":"Journal of Theoretical Biology"},{"issue":"35","key":"pcbi.1011383.ref031","doi-asserted-by":"crossref","first-page":"17393","DOI":"10.1073\/pnas.1902178116","article-title":"A dynamical motif comprising the interactions between antigens and CD8 T cells may underlie the outcomes of viral infections","volume":"116","author":"S Baral","year":"2019","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"47","key":"pcbi.1011383.ref032","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc7112","article-title":"Potency and timing of antiviral therapy as determinants of duration of SARS\u2013CoV\u20132 shedding and intensity of inflammatory response","volume":"6","author":"A Goyal","year":"2020","journal-title":"Sci Adv"},{"issue":"49","key":"pcbi.1011383.ref033","doi-asserted-by":"crossref","first-page":"e2111477118","DOI":"10.1073\/pnas.2111477118","article-title":"In vivo kinetics of SARS\u2013CoV\u20132 infection and its relationship with a person\u2019s infectiousness","volume":"118","author":"R Ke","year":"2021","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"pcbi.1011383.ref034","first-page":"118","article-title":"Modeling SARS\u2013CoV\u20132 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort","author":"N N\u00e9ant","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pcbi.1011383.ref035","doi-asserted-by":"crossref","first-page":"e09488","DOI":"10.1016\/j.heliyon.2022.e09488","article-title":"A multicompartment mathematical model based on host immunity for dissecting COVID\u201319 heterogeneity","volume":"8","author":"J Li","year":"2022","journal-title":"Heliyon"},{"issue":"1","key":"pcbi.1011383.ref036","doi-asserted-by":"crossref","first-page":"14210","DOI":"10.1038\/s41598-022-18244-2","article-title":"A simple model of COVID\u201319 explains disease severity and the effect of treatments","volume":"12","author":"S Sanche","year":"2022","journal-title":"Scientific Reports"},{"issue":"6","key":"pcbi.1011383.ref037","doi-asserted-by":"crossref","first-page":"e1010630","DOI":"10.1371\/journal.ppat.1010630","article-title":"Modeling recapitulates the heterogeneous outcomes of SARS\u2013CoV\u20132 infection and quantifies the differences in the innate immune and CD8 T\u2013cell responses between patients experiencing mild and severe symptoms","volume":"18","author":"B Chatterjee","year":"2022","journal-title":"PLOS Pathogens"},{"issue":"11","key":"pcbi.1011383.ref038","doi-asserted-by":"crossref","first-page":"e1009587","DOI":"10.1371\/journal.pcbi.1009587","article-title":"Data\u2013driven multi\u2013scale mathematical modeling of SARS\u2013CoV\u20132 infection reveals heterogeneity among COVID\u201319 patients","volume":"17","author":"S Wang","year":"2021","journal-title":"PLoS Comput Biol"},{"key":"pcbi.1011383.ref039","first-page":"11","article-title":"Modelling of the Innate and Adaptive Immune Response to SARS Viral Infection, Cytokine Storm and Vaccination","author":"C Leon","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"pcbi.1011383.ref040","doi-asserted-by":"crossref","first-page":"e1009753","DOI":"10.1371\/journal.ppat.1009753","article-title":"COVID\u201319 virtual patient cohort suggests immune mechanisms driving disease outcomes","volume":"17","author":"AL Jenner","year":"2021","journal-title":"PLOS Pathogens"},{"issue":"10","key":"pcbi.1011383.ref041","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.it.2021.08.003","article-title":"Examining the cooperativity mode of antibody and CD8(+) T cell immune responses for vaccinology","volume":"42","author":"G Bocharov","year":"2021","journal-title":"Trends Immunol"},{"issue":"2","key":"pcbi.1011383.ref042","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.immuni.2021.01.014","article-title":"B cell memory: understanding COVID\u201319","volume":"54","author":"I Quast","year":"2021","journal-title":"Immunity"},{"issue":"2","key":"pcbi.1011383.ref043","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"F McNab","year":"2015","journal-title":"Nature Reviews Immunology"},{"issue":"7","key":"pcbi.1011383.ref044","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.chom.2021.05.004","article-title":"Innate immune and inflammatory responses to SARS\u2013CoV\u20132: Implications for COVID\u201319.","volume":"29","author":"SA Lowery","year":"2021","journal-title":"Cell Host & Microbe"},{"issue":"1","key":"pcbi.1011383.ref045","doi-asserted-by":"crossref","first-page":"108234","DOI":"10.1016\/j.celrep.2020.108234","article-title":"Evasion of Type I Interferon by SARS\u2013CoV\u20132","volume":"33","author":"H Xia","year":"2020","journal-title":"Cell Rep"},{"issue":"5","key":"pcbi.1011383.ref046","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced Host Response to SARS\u2013CoV\u20132 Drives Development of COVID\u201319","volume":"181","author":"D Blanco\u2013Melo","year":"2020","journal-title":"Cell"},{"issue":"1","key":"pcbi.1011383.ref047","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41590-020-00840-x","article-title":"Untuned antiviral immunity in COVID\u201319 revealed by temporal type I\/III interferon patterns and flu comparison","volume":"22","author":"E Galani I\u2013","year":"2021","journal-title":"Nature Immunology"},{"key":"pcbi.1011383.ref048","first-page":"13","article-title":"Circulating Type I Interferon Levels in the Early Phase of COVID\u201319 Are Associated With the Development of Respiratory Failure","author":"K Nagaoka","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"7821","key":"pcbi.1011383.ref049","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID\u201319","volume":"584","author":"C Lucas","year":"2020","journal-title":"Nature"},{"key":"pcbi.1011383.ref050","article-title":"Interferon alpha\u2013based combinations suppress SARS\u2013CoV\u20132 infection in vitro and in vivo","author":"I Aleksandr","year":"2021","journal-title":"bioRxiv"},{"issue":"8","key":"pcbi.1011383.ref051","doi-asserted-by":"crossref","first-page":"e2111600119","DOI":"10.1073\/pnas.2111600119","article-title":"Differential interferon\u2013\u03b1 subtype induced immune signatures are associated with suppression of SARS\u2013CoV\u20132 infection","volume":"119","author":"J Schuhenn","year":"2022","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"1","key":"pcbi.1011383.ref052","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS\u2013CoV.","volume":"11","author":"TP Sheahan","year":"2020","journal-title":"Nat Commun"},{"issue":"23","key":"pcbi.1011383.ref053","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine Storm","volume":"383","author":"DC Fajgenbaum","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"pcbi.1011383.ref054","doi-asserted-by":"crossref","first-page":"9696","DOI":"10.1073\/pnas.2004911117","article-title":"Demographic science aids in understanding the spread and fatality rates of COVID\u201319","volume":"117","author":"JB Dowd","year":"2020","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"5","key":"pcbi.1011383.ref055","doi-asserted-by":"crossref","first-page":"2000547","DOI":"10.1183\/13993003.00547-2020","article-title":"Comorbidity and its impact on 1590 patients with COVID\u201319 in China: a nationwide analysis","volume":"55","author":"W\u2013J Guan","year":"2020","journal-title":"Eur Respir J"},{"key":"pcbi.1011383.ref056","doi-asserted-by":"crossref","first-page":"102763","DOI":"10.1016\/j.ebiom.2020.102763","article-title":"Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS\u2013CoV\u20132 infected patients","volume":"55","author":"J Liu","year":"2020","journal-title":"EBioMedicine"},{"issue":"10","key":"pcbi.1011383.ref057","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1136\/thoraxjnl-2020-216256","article-title":"Distinct cellular immune profiles in the airways and blood of critically ill patients with COVID\u201319","volume":"76","author":"A Saris","year":"2021","journal-title":"Thorax"},{"issue":"6","key":"pcbi.1011383.ref058","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single\u2013cell landscape of bronchoalveolar immune cells in patients with COVID\u201319","volume":"26","author":"M Liao","year":"2020","journal-title":"Nature Medicine"},{"key":"pcbi.1011383.ref059","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0951-8320(03)00058-9","article-title":"Latin hypercube sampling and the propagation of uncertainty in analyses of complex systems","volume":"81","author":"JC Helton","year":"2002","journal-title":"Reliability Engineering & System Safety"},{"issue":"1","key":"pcbi.1011383.ref060","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1186\/s12879-021-07002-w","article-title":"Prolonged viral shedding of SARS\u2013CoV\u20132 and related factors in symptomatic COVID\u201319 patients: a prospective study","volume":"21","author":"H Long","year":"2021","journal-title":"BMC Infectious Diseases"},{"key":"pcbi.1011383.ref061","article-title":"SARS\u2013CoV\u20132 viral load and shedding kinetics","author":"O Puhach","year":"2022","journal-title":"Nature Reviews Microbiology"},{"issue":"1","key":"pcbi.1011383.ref062","doi-asserted-by":"crossref","first-page":"2002724","DOI":"10.1183\/13993003.02724-2020","article-title":"Dynamics of SARS\u2013CoV\u20132 shedding in the respiratory tract depends on the severity of disease in COVID\u201319 patients","volume":"58","author":"D Munker","year":"2021","journal-title":"European Respiratory Journal"},{"key":"pcbi.1011383.ref063","doi-asserted-by":"crossref","first-page":"m1443","DOI":"10.1136\/bmj.m1443","article-title":"Viral load dynamics and disease severity in patients infected with SARS\u2013CoV\u20132 in Zhejiang province, China, January\u2013March 2020: retrospective cohort study","volume":"369","author":"S Zheng","year":"2020","journal-title":"Bmj"},{"issue":"6","key":"pcbi.1011383.ref064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rmv.2141","article-title":"Interleukin\u20136 in Covid\u201319: A systematic review and meta\u2013analysis","volume":"30","author":"EA Coomes","year":"2020","journal-title":"Reviews in Medical Virology"},{"issue":"10","key":"pcbi.1011383.ref065","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID\u201319 severity and survival","volume":"26","author":"DM Del Valle","year":"2020","journal-title":"Nature Medicine"},{"issue":"7","key":"pcbi.1011383.ref066","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","article-title":"Case Study: Prolonged Infectious SARS\u2013CoV\u20132 Shedding from an Asymptomatic Immunocompromised Individual with Cancer","volume":"183","author":"VA Avanzato","year":"2020","journal-title":"Cell"},{"issue":"7853","key":"pcbi.1011383.ref067","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","article-title":"SARS\u2013CoV\u20132 evolution during treatment of chronic infection","volume":"592","author":"SA Kemp","year":"2021","journal-title":"Nature"},{"issue":"6","key":"pcbi.1011383.ref068","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1473-3099(20)30232-2","article-title":"Viral dynamics in mild and severe cases of COVID\u201319","volume":"20","author":"Y Liu","year":"2020","journal-title":"The Lancet Infectious Diseases"},{"key":"pcbi.1011383.ref069","article-title":"Saliva viral load is a dynamic unifying correlate of COVID\u201319 severity and mortality","author":"J Silva","year":"2021","journal-title":"medRxiv"},{"issue":"6","key":"pcbi.1011383.ref070","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s10096-020-04150-w","article-title":"Impact of viral load at admission on the development of respiratory failure in hospitalized patients with SARS\u2013CoV\u20132 infection","volume":"40","author":"C de la Calle","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"pcbi.1011383.ref071","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S2213-2600(20)30354-4","article-title":"SARS\u2013CoV\u20132 viral load predicts COVID\u201319 mortality","volume":"8","author":"E Pujadas","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"issue":"1","key":"pcbi.1011383.ref072","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41392-020-00301-9","article-title":"Disease severity dictates SARS\u2013CoV\u20132\u2013specific neutralizing antibody responses in COVID\u201319","volume":"5","author":"X Chen","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"54","key":"pcbi.1011383.ref073","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abe0240","article-title":"Defining the features and duration of antibody responses to SARS\u2013CoV\u20132 infection associated with disease severity and outcome","volume":"5","author":"K R\u00f6ltgen","year":"2020","journal-title":"Sci Immunol"},{"key":"pcbi.1011383.ref074","doi-asserted-by":"crossref","first-page":"m4838","DOI":"10.1136\/bmj.m4838","article-title":"Covid\u201319 vaccines: delivering protective immunity","author":"HF Sewell","year":"2020","journal-title":"BMJ"},{"issue":"10","key":"pcbi.1011383.ref075","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41423-021-00743-3","article-title":"SARS\u2013CoV\u20132\u2013specific T cells in infection and vaccination","volume":"18","author":"A Bertoletti","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"10","key":"pcbi.1011383.ref076","article-title":"Mathematical Modeling of Vaccines That Prevent SARS\u2013CoV\u20132 Transmission","volume":"13","author":"DA Swan","year":"2021","journal-title":"Viruses"},{"issue":"6","key":"pcbi.1011383.ref077","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41591-020-0858-8","article-title":"T cell\u2013inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers","volume":"26","author":"PS Arunachalam","year":"2020","journal-title":"Nat Med"},{"issue":"7894","key":"pcbi.1011383.ref078","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41586-021-04232-5","article-title":"A COVID\u201319 peptide vaccine for the induction of SARS\u2013CoV\u20132 T cell immunity","volume":"601","author":"JS Heitmann","year":"2022","journal-title":"Nature"},{"issue":"20","key":"pcbi.1011383.ref079","doi-asserted-by":"crossref","first-page":"e2118312119","DOI":"10.1073\/pnas.2118312119","article-title":"Vaccine\u2013induced systemic and mucosal T cell immunity to SARS\u2013CoV\u20132 viral variants","volume":"119","author":"B Kingstad\u2013Bakke","year":"2022","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"10","key":"pcbi.1011383.ref080","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.it.2021.08.003","article-title":"Examining the cooperativity mode of antibody and CD8+ T cell immune responses for vaccinology","volume":"42","author":"G Bocharov","year":"2021","journal-title":"Trends in Immunology"},{"key":"pcbi.1011383.ref081","article-title":"SARS\u2013CoV\u20132 Omicron Variant: ACE2 Binding, Cryo\u2013EM Structure of Spike Protein\u2013ACE2 Complex and Antibody Evasion","author":"D Mannar","year":"2021","journal-title":"bioRxiv"},{"issue":"12","key":"pcbi.1011383.ref082","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41591-021-01575-4","article-title":"Viral loads of Delta\u2013variant SARS\u2013CoV\u20132 breakthrough infections after vaccination and booster with BNT162b2","volume":"27","author":"M Levine\u2013Tiefenbrun","year":"2021","journal-title":"Nature Medicine"},{"issue":"26","key":"pcbi.1011383.ref083","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1056\/NEJMc2102507","article-title":"Viral Dynamics of SARS\u2013CoV\u20132 Variants in Vaccinated and Unvaccinated Persons","volume":"385","author":"SM Kissler","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"pcbi.1011383.ref084","first-page":"2021","article-title":"Demographic characteristics of SARS\u2013CoV\u20132 B.1.617.2 (Delta) variant infections in Indian population","author":"A Kumar","year":"2021","journal-title":"medRxiv"},{"key":"pcbi.1011383.ref085","first-page":"12","article-title":"Infections with the SARS\u2013CoV\u20132 Delta variant exhibit fourfold increased viral loads in the upper airways compared to Alpha or non\u2013variants of concern","author":"CJH von Wintersdorff","year":"2022","journal-title":"Scientific Reports"},{"key":"pcbi.1011383.ref086","author":"M Petra","year":"2021","journal-title":"Nature Portfolio"},{"issue":"7883","key":"pcbi.1011383.ref087","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","article-title":"SARS\u2013CoV\u20132 B.1.617.2 Delta variant replication and immune evasion","volume":"599","author":"P Mlcochova","year":"2021","journal-title":"Nature"},{"issue":"7902","key":"pcbi.1011383.ref088","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41586-022-04479-6","article-title":"SARS\u2013CoV\u20132 Omicron variant replication in human bronchus and lung ex vivo","volume":"603","author":"KPY Hui","year":"2022","journal-title":"Nature"},{"issue":"1","key":"pcbi.1011383.ref089","doi-asserted-by":"crossref","first-page":"e1120","DOI":"10.1093\/cid\/ciab754","article-title":"Severity of Severe Acute Respiratory System Coronavirus 2 (SARS\u2013CoV\u20132) Alpha Variant (B.1.1.7) in England","volume":"75","author":"DJ Grint","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"11","key":"pcbi.1011383.ref090","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1473-3099(21)00318-2","article-title":"Mortality and critical care unit admission associated with the SARS\u2013CoV\u20132 lineage B.1.1.7 in England: an observational cohort study","volume":"21","author":"M Patone","year":"2021","journal-title":"The Lancet Infectious Diseases"},{"issue":"1","key":"pcbi.1011383.ref091","doi-asserted-by":"crossref","first-page":"e1128","DOI":"10.1093\/cid\/ciab721","article-title":"Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS\u2013CoV\u20132) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta)","volume":"75","author":"SWX Ong","year":"2022","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"pcbi.1011383.ref092","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1473-3099(21)00475-8","article-title":"Hospital admission and emergency care attendance risk for SARS\u2013CoV\u20132 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study","volume":"22","author":"KA Twohig","year":"2022","journal-title":"The Lancet Infectious Diseases"},{"issue":"42","key":"pcbi.1011383.ref093","doi-asserted-by":"crossref","first-page":"E1619","DOI":"10.1503\/cmaj.211248","article-title":"Evaluation of the relative virulence of novel SARS\u2013CoV\u20132 variants: a retrospective cohort study in Ontario, Canada","volume":"193","author":"NF David","year":"2021","journal-title":"Canadian Medical Association Journal"},{"key":"pcbi.1011383.ref094","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.15585\/mmwr.mm7043e1","article-title":"everity of Disease Among Adults Hospitalized with Laboratory\u2013Confirmed COVID\u201319 Before and During the Period of SARS\u2013CoV\u20132 B.1.617.2 (Delta) Predominance\u2014COVID\u2013NET, 14 States, January\u2013August 2021","volume":"70","author":"PK Taylor CA","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pcbi.1011383.ref095","doi-asserted-by":"crossref","first-page":"792135","DOI":"10.3389\/fmed.2021.792135","article-title":"Differences in Clinical Characteristics Between Delta Variant and Wild\u2013Type SARS\u2013CoV\u20132 Infected Patients","volume":"8","author":"Z Hu","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"pcbi.1011383.ref096","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/CM9.0000000000000819","article-title":"Chinese\u2013diagnosis\u2013and\u2013treatment\u2013guideline\u2013for\u2013COVID\u201319\u2013Version\u20137. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)","volume":"133","year":"2020","journal-title":"Chin Med J (Engl)"},{"issue":"47","key":"pcbi.1011383.ref097","doi-asserted-by":"crossref","first-page":"eabc7112","DOI":"10.1126\/sciadv.abc7112","article-title":"Potency and timing of antiviral therapy as determinants of duration of SARS\u2013CoV\u20132 shedding and intensity of inflammatory response","volume":"6","author":"A Goyal","year":"2020","journal-title":"Science Advances"},{"issue":"4","key":"pcbi.1011383.ref098","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.immuni.2020.07.026","article-title":"Acute SARS\u2013CoV\u20132 Infection Impairs Dendritic Cell and T Cell Responses","volume":"53","author":"R Zhou","year":"2020","journal-title":"Immunity"},{"issue":"20","key":"pcbi.1011383.ref099","doi-asserted-by":"crossref","first-page":"e2118312119","DOI":"10.1073\/pnas.2118312119","article-title":"Vaccine\u2013induced systemic and mucosal T cell immunity to SARS\u2013CoV\u20132 viral variants","volume":"119","author":"B Kingstad\u2013Bakke","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6608","key":"pcbi.1011383.ref100","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1126\/science.add2897","article-title":"T cell immunity to COVID\u201319 vaccines","volume":"377","author":"EJ Wherry","year":"2022","journal-title":"Science"},{"issue":"77","key":"pcbi.1011383.ref101","doi-asserted-by":"crossref","first-page":"eabq7647","DOI":"10.1126\/sciimmunol.abq7647","article-title":"CD8 T cells contribute to vaccine protection against SARS\u2013CoV\u20132 in macaques","volume":"7","author":"J Liu","journal-title":"Science Immunology"},{"issue":"6","key":"pcbi.1011383.ref102","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41591-020-0858-8","article-title":"T cell\u2013inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers","volume":"26","author":"PS Arunachalam","year":"2020","journal-title":"Nature Medicine"},{"key":"pcbi.1011383.ref103","article-title":"SARS\u2013CoV\u20132 (COVID\u201319) by the numbers.","volume":"9","author":"YM Bar\u2013On","year":"2020","journal-title":"eLife"},{"issue":"1","key":"pcbi.1011383.ref104","doi-asserted-by":"crossref","first-page":"e1009778","DOI":"10.1371\/journal.pcbi.1009778","article-title":"Longitudinally monitored immune biomarkers predict the timing of COVID\u201319 outcomes","volume":"18","author":"G Lasso","year":"2022","journal-title":"PLOS Computational Biology"},{"issue":"3","key":"pcbi.1011383.ref105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/bmjebm-2020-111536","article-title":"Biomarkers and outcomes of COVID\u201319 hospitalisations: systematic review and meta\u2013analysis","volume":"26","author":"M Preeti","year":"2021","journal-title":"BMJ Evidence\u2013Based Medicine"},{"issue":"6","key":"pcbi.1011383.ref106","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/bioinformatics\/btab856","article-title":"CoV\u2013Spectrum: Analysis of Globally Shared SARS\u2013CoV\u20132 Data to Identify and Characterize New Variants","volume":"38","author":"C Chen","year":"2021","journal-title":"Bioinformatics"},{"issue":"7821","key":"pcbi.1011383.ref107","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID\u201319\u2013related death using OpenSAFELY","volume":"584","author":"EJ Williamson","year":"2020","journal-title":"Nature"},{"issue":"16","key":"pcbi.1011383.ref108","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"SL Maude","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"pcbi.1011383.ref109","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","article-title":"SciPy 1.0: fundamental algorithms for scientific computing in Python","volume":"17","author":"P Virtanen","year":"2020","journal-title":"Nature Methods"},{"issue":"2","key":"pcbi.1011383.ref110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS\u2013CoV\u20132 vaccine in healthy adults aged 18\u201359 years: a randomised, double\u2013blind, placebo\u2013controlled, phase 1\/2 clinical trial","volume":"21","author":"Y Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"10249","key":"pcbi.1011383.ref111","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV\u201319 vaccine against SARS\u2013CoV\u20132: a preliminary report of a phase 1\/2, single\u2013blind, randomised controlled trial","volume":"396","author":"PM Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"10269","key":"pcbi.1011383.ref112","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV\u201319 vaccine (AZD1222) against SARS\u2013CoV\u20132: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"M Voysey","year":"2021","journal-title":"Lancet"},{"issue":"7868","key":"pcbi.1011383.ref113","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly\u2013specific T cells in humans","volume":"595","author":"U Sahin","year":"2021","journal-title":"Nature"},{"issue":"27","key":"pcbi.1011383.ref114","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid\u201319 Vaccine","volume":"383","author":"FP Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"pcbi.1011383.ref115","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","article-title":"Reduced neutralization of SARS\u2013CoV\u20132 B.1.617 by vaccine and convalescent serum","volume":"184","author":"C Liu","year":"2021","journal-title":"Cell"},{"issue":"26","key":"pcbi.1011383.ref116","article-title":"Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech\/Pfizer) vaccination in health care workers, Israel","volume":"26","author":"Y Lustig","year":"2021","journal-title":"Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1011383","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1011383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T17:48:35Z","timestamp":1694713715000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1011383"}},"subtitle":[],"editor":[{"given":"Adrianne L.","family":"Jenner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":116,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1011383","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pcbi.1011383","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}